EQL Pharma AB (publ) (STO: EQL)

EQL Pharma AB Revenue

EQL Pharma AB had revenue of 85.25M SEK in the quarter ending September 30, 2024, with 42.99% growth. This brings the company's revenue in the last twelve months to 316.38M, up 23.42% year-over-year. In the fiscal year ending March 31, 2024, EQL Pharma AB had annual revenue of 264.17M with 1.64% growth.

• Revenue (ttm): 316.38M
• Revenue Growth: +23.42%
• P/S Ratio: 7.33
• Revenue / Employee: 15.82M
• Employees: 21
• Market Cap: 2.32B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2024	264.17M	4.26M	1.64%
Mar 31, 2023	259.91M	-149.84M	-36.57%
Mar 31, 2022	409.75M	230.61M	128.73%
Mar 31, 2021	179.14M	107.11M	148.70%
Mar 31, 2020	72.03M	22.28M	44.77%